Montek (Sodium Molybdate (99mo))

Sodium molybdate releases molybdate ions that serve as essential cofactors for molybdo‑enzymes such as sulfite oxidase, xanthine oxidase and aldehyde oxidase. By providing these ions, the compound supports the catalytic conversion of specific substrates, enabling both normal metabolic processes and laboratory assays that depend on molybdenum‑dependent reactions.

The dose of Montek is determined by the prescribing clinician based on the intended research or diagnostic purpose, the route of administration, and individual patient factors. No fixed dosing regimen is provided in public sources.

Safety data for sodium molybdate in pregnancy or lactation are limited. It should only be used when the potential benefit justifies any possible risk to the mother or infant, and only under the guidance of a qualified healthcare professional.

To order Montek, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Montek’s sodium molybdate formulation offers a well‑characterised source of molybdenum ions suitable for both intravenous and ocular use. Compared with other molybdenum compounds, it provides a sterile aqueous solution that is compatible with standard clinical administration sets, while alternative agents may be less soluble or lack regulatory clearance for human use.

Montek should be stored at ambient temperature, preferably below 25 °C, in its original sealed container. Protect the product from moisture, direct sunlight and extreme temperature fluctuations. Do not freeze the solution, and handle it using aseptic technique to maintain sterility.

Montek is supplied as a sterile solution for administration by a qualified healthcare professional. It can be given as an intravenous infusion or injected into the ocular compartment, following the specific protocol dictated by the clinical or research procedure.

Serious risks include anaphylactic or severe hypersensitivity reactions, acute renal impairment, ocular toxicity that may affect vision, and severe hypotension or thrombophlebitis. Immediate medical attention is required if any of these events occur.

Montek is contraindicated in individuals with a known allergy to sodium molybdate or other molybdenum compounds, in patients with severe renal failure unless specifically directed, and in pregnant or breastfeeding women when safer alternatives are available.